You are here

Article info

Article menu
Download PDFPDF
Special communication
Analysis of FDA’s Vuse market authorisation: limitations and opportunities

Authors

  1. Correspondence to Dr Andrew B Meshnick, Pediatrics, University of Vermont Children's Hospital, Burlington, VT 05401, USA; abm75{at}georgetown.edu
View Full Text

Citation

Meshnick AB, Faricy LE, Lushniak BD
Analysis of FDA’s Vuse market authorisation: limitations and opportunities
Tobacco Control 2024;33:e116-e121.

Publication history

  • Received May 20, 2022
  • Accepted November 4, 2022
  • First published February 9, 2023.
Online issue publication 
March 19, 2024

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.